Gastrointestinal Stromal Tumors (GISTs) Treatment Market, by Treatment Options (Surgery, Radiation Therapy, Targeted Drug Therapies, Immunotherapy, Chemotherapy) and, by End User (Hospitals, Orthopedic Clinics, Diagnostic Centers, Specialty Clinics, Others): Opportunity Analysis and Industry Forecast, 2023-2032

The Gastrointestinal stromal tumors (gists) treatment industry market report offers a comprehensive study on the global market size & forecast, segmental splits, and further classification into regional & country-level. Furthermore, it highlights the market dynamics & trends, Porters’ five force analysis, competitive landscape, and market share analysis.

Gastrointestinal stromal tumors (gists) treatment industry market Revenue ($Million), By Segment, 2023 to 2032

Graph for representation purpose only

Segmental Outlook

The global Gastrointestinal stromal tumors (gists) treatment industry market is segmented on the basis of by treatment options, by end user. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (the UK, Germany, France, Spain, Italy, and rest of Europe), Asia-Pacific (China, Japan, Australia, South Korea, India, and rest of Asia-Pacific), and LAMEA (Latin America, the Middle East, and Africa).

The segmental analysis includes real-time and forecast in both qualitative and quantitative terms. This helps clients understand the most lucrative segments for investors to capitalize on in the market.

Gastrointestinal stromal tumors (gists) treatment industry market Revenue ($Million), By Type, 2023 to 2032

Graph for representation purpose only

Competitive Scenario

The report includes an in-depth analysis of the major market players operating across the globe, along with an outlook on top player positioning. Furthermore, the report focuses on developmental strategies such as mergers & acquisitions, product/service launches, and collaborations adopted by the market players to maintain and enhance their foothold in the market.

Key players identified in this report are Johnson and Johnson Services, Inc., Novartis AG, Pfizer, Inc., Roche Holding AG, Eli Lilly and Company, Celgene Corporation, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc., Merck and Co., Inc., Bristol Myers Squibb Company

Report Coverage

• Market Size Projections: 2023 to 2032

• Major Segments Covered: by treatment options, by end user

• Market Dynamics and Trends

• Competitive Landscape Reporting

Note

• Clients have the liberty to customize the list as per their requirements.

• AMR offers 20% free customization policy and clients can request AMR for a tailor-made report by considering their requirements. However, the modification will be finalized post a quick feasibility check.

  Gastrointestinal Stromal Tumors (GISTs) Treatment Market Report Highlights

Aspects	Details
By Treatment Options	Surgery Radiation Therapy Targeted Drug Therapies Immunotherapy Chemotherapy
By End User	Hospitals Orthopedic Clinics Diagnostic Centers Specialty Clinics Others
By Region	North America  (U.S., Canada, Mexico) Europe  (France, Germany, Italy, Spain, UK, Russia, Rest of Europe) Asia-Pacific  (China, Japan, India, South Korea, Australia, Thailand, Malaysia, Indonesia, Rest of Asia-Pacific) LAMEA  (Brazil, South Africa, Saudi Arabia, UAE, Argentina, Rest of LAMEA)
Key Market Players	GlaxoSmithKline plc., F. Hoffmann-La Roche Ltd., Celgene Corporation, Eli Lilly and Company, Johnson and Johnson Services, Roche Holding AG, Bristol Myers Squibb Company, Pfizer, Novartis AG, Merck and Co.

^*Terms and Conditions Apply